Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Imerys signs agreement to end talc litigation in the United States

May 21, 2020 By Law Offices of Thomas J. Lamb, P.A.

Imerys announced on May 15 that it had reached agreement on a plan to end the [ talcum powder – asbestos litigation ] that resulted in the Chapter 11 (receivership) placement of its North American subsidiaries Imerys Talc America, Imerys Talc Vermont and Imerys Talc Canada. The group had announced at the end of 2018 that these three subsidiaries, representing around 3% of turnover, had placed themselves under the protection of “Chapter 11” to settle their historic disputes.

Talc, used in particular for infants, but also by certain women on their genitals to reduce humidity and odors, is at the heart of [ talcum powder – asbestos litigation ] in the United States where women accuse the product – and its producers Imerys and Johnson & Johnson – for causing cancer. In addition, Imerys had recognized in 2019 that the shutdown of its Willsboro plant was linked to the discovery of traces of asbestos in certain products.

The agreement announced on May 15 provides for a restructuring plan, filed with the federal district court of Delaware, where the procedure of “chapter 11” is underway for the three North American talc subsidiaries of the group. “Once the necessary approvals have been obtained, the Talc subsidiaries will exit from the” Chapter 11 “regime and the group will be released from all existing and future liabilities linked to the past activities of the Talc subsidiaries, these liabilities being transferred to a trust specially created for this purpose. effect, “said Imerys in a statement.

The approval process for this plan, negotiated with representatives of the court-appointed plaintiffs, requires a qualified majority vote of [ talcum powder – asbestos litigation ] plaintiffs. Then this approval must be confirmed by the competent American courts. Imerys is hoping for final approval within a timeframe that would allow its affected affiliates to exit Chapter 11 before the end of 2020. These affiliates, which generated revenues of $ 162 million and an Ebitda of 34 million dollars in 2019, will have to sell their assets.

[Article continues at original source]

 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos-infused talc, mesothelioma, mesothelioma lawsuits, talc, talcum powder

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.